Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 47, Issue 1, pp 155–156 | Cite as

Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation

  • Roberto CastelliEmail author
  • Paolo Gallipoli
  • Riccardo Schiavon
  • Thomas Teatini
  • Giorgio Lambertenghi Deliliers
  • Luigi Bergamaschini
Letter to the Editor

Dear Editor,

We have previously described an High prevalence of heparin induced thrombocytopenia with thrombosis (HITT) among patients with essential thrombocythemia carrying V 617 F mutation [1]. The JAK2 V617F mutation has been demonstrated to be the main molecular marker of Philadelphia-negative chronic myeloproliferative neoplasms, occurring in > 90% of patients with polycythemia Vera and in about half of all of the patients with ET [2, 3, 4, 5].

We studied 108 ET patients on heparin for treatment of previous thrombotic events or in thromboprophilaxis. The study was conducted according to good clinical and laboratory practice rules and the principles of the Declaration of Helsinki, and the Ospedale Sacco and IRCCS Policlinico of Milan Ethics Review Committee approved the protocol. Fifty-eight of them carried JAK 2 V617F mutation while 50 patients were wild type for the mutation. Ten patients, among those with JAK 2 V617F mutation after a median of 10 days from heparin treatment...

References

  1. 1.
    Castelli R, Gallipoli P, Schiavon R, Teatini T, Deliliers GL, Bergamaschini L (2018) High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. J Thromb Thrombolysis 45(1):106–113.  https://doi.org/10.1007/s11239-017-1566-1 CrossRefGoogle Scholar
  2. 2.
    Antonioli E, Guglielmelli P, Poli G et al (2008) Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93(1):41–48.  https://doi.org/10.3324/haematol.11653 CrossRefGoogle Scholar
  3. 3.
    Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2 617V> F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110(3):840–846.  https://doi.org/10.1182/blood-2006-12-064287 CrossRefGoogle Scholar
  4. 4.
    Colombo R, Gallipoli P, Castelli R (2014) Thrombosis and hemostatic abnormalities in hematological malignancies. Clin Lymphoma Myeloma Leuk 14(6):441–450CrossRefGoogle Scholar
  5. 5.
    Castelli R, Ferrari B, Cortelezzi A, Guariglia A (2010) Thromboembolic complications in malignant haematological disorders. Curr Vasc Pharmacol 4:482–494CrossRefGoogle Scholar
  6. 6.
    De Stefano V, Za T, Rossi E et al (2010) Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Ann Hematol 89(2):141–146.  https://doi.org/10.1007/s00277-009-0788-5 CrossRefGoogle Scholar
  7. 7.
    De Stefano V, Za T, Rossi E et al (2009) Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica 94(5):733–737.  https://doi.org/10.3324/haematol.13869 CrossRefGoogle Scholar
  8. 8.
    Takahaski K, Patel P (2013) V617F detection and allele burden measurement in peripheral blood and bone marrow aspirate in patients with myeloproliferative neoplasms. Blood 122(23):3784–3786CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Roberto Castelli
    • 1
    Email author
  • Paolo Gallipoli
    • 2
  • Riccardo Schiavon
    • 1
  • Thomas Teatini
    • 1
  • Giorgio Lambertenghi Deliliers
    • 3
  • Luigi Bergamaschini
    • 1
  1. 1.Department of Biomedical and Clinical Sciences Luigi Sacco, Luigi Sacco HospitalUniversity of MilanMilanItaly
  2. 2.Department of Haematology, Cambridge Institute for Medical ResearchCambridge UniversityCambridgeUK
  3. 3.Fondazione Matarelli MilanoMilanItaly

Personalised recommendations